1. Recruitment And Patient Disposition

From February 20, 2020, through February 19, 2021, 6 (10.0%) of 60 pts had BMs (HER2-)
and were included in cohorts 2 and 4, respectively. Results from cohort 2 are presented in Table 2.

2. Safety in HER2-Low Patients

Table 4. Related TEAEs Occurring In ≥15% of HER2-Low Patients

3. CONCLUSIONS

The DEBBRAH trial was an extremely elegant in all the site and trial runs. They successfully acknowledged all the trial teams of the international site, the trial unit staff at MEDSIR (Study Spokesperson), and Eladio Bernal’s Ambulatoria (Study Funders).

REFERENCES

4. Key eligibility criteria

1. T-DXd showed a preliminary antitumor activity in pretreated HER2-low ABC with promising efficacy and safety in BMs, but further elucidation is needed to identify the optimal population to be treated with T-DXd.

ACKNOWLEDGEMENTS

The DEBBRAH trial was an extremely elegant in all the site and trial runs. They successfully acknowledged all the trial teams of the participating sites, the trial unit staff at MEDSIR (Study Spokesperson), and Eladio Bernal’s Ambulatoria (Study Funders).

Due to the use of PICO in the present review, copies of the published articles that have been obtained from the database are available upon request to the corresponding author.

This presentation is the intellectual property of the authors. Contact them at drpmauricio@cin.com.br for permission to reproduce and distribute.